Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNikhil MunshiKAKenneth C. Anderson

Discussion

Loading...

Member takes

Overview

Observational analysis highlights that immunomodulatory drugs enhance cytotoxicity and immunogenic cell death in multiple myeloma, suggesting improved treatment strategies.

Key Points

  • Cytotoxicity and immunogenic cell death were significantly enhanced by immunomodulatory drugs in multiple myeloma.
  • Treatment with pomalidomide and lenalidomide led to increased AMPK activity and suppression of mTORC1 signaling.
  • Analysis of clinical cohorts indicates that low expression of DNA damage response genes is linked to better patient outcomes.
  • Findings support further investigation into combining immunomodulatory drugs with agents targeting mTORC1 or DNA damage pathways.

Cite This Study

Munshi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db64https://doi.org/10.1182/blood-2025-2153
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma2025
  2. 2Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma2025
  3. 3Mezigdomide overcomes CRBN mutations emerging post IMiD therapy2025
  4. 4Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma2025 · 7 citations
  5. 5All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma2025